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In man, activated N-, K- and H-ras oncogenes have been
found in around 30% of the solid tumours tested. An
exon known as IDX, which has been described previously
and is located between exon 3 and exon 4A of the c-H-
ras pre-mRNA, allows an alternative splicing process
that results in the synthesis of the mRNA of a putative
protein named p19. It has been suggested that this
alternative pathway is less tumorigenic than that which
results in the activation of p21. We have used the
mammalian trans-splicing mechanism as a tool with
which to modulate this particular pre-mRNA processing
to produce mRNA similar to that of mature p19 RNA.
The E4A exon of the activated H-ras gene was found to
be a good target for external trans-splicing. We
reprogrammed the rat carnitine octanoyltransferase exon
2 to specifically invade the terminal region of H-ras.
Assays performed with this reprogrammed trans-exon
showed that the trans-splicing product was obtained in
competition with cis-splicing of the D intron of the H-ras
gene, and was associated with concomitant down-
modulation of D intron cis-splicing. We also found that
the exon 4A of the human c-H-ras gene underwent
successive trans-splicing rounds with an external exon.
Oncogene (2001) 20, 3683 – 3694.
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Introduction
The c-H-ras gene, and other members of the ras
family (N- and K-ras) are proto-oncogenes, the
activated forms of which are present in approximately
30% of all solid human tumours that have been
examined (reviewed in Barbacid, 1987). The presence
of H-ras activated genes varies from tumour to
tumour, but it appears to be activated in a variety
of induced cancers in dierent animal model systems,
with an incidence of between 80 and 100%, depending
upon the location of the tumour (mammary, skin or
hepatocellular carcinomas). This suggests that H-ras
and other ras-family oncogenes (N-ras and K-ras) are
likely to participate in the initiation of tumour
development (Barbacid, 1987). The p21 protein, which
is the product of c-H-ras mRNA, belongs to the G-
protein family and has an important function in the
transduction of external mitogenic signals to the cell.
p21 binds to the membrane through its C-terminal
domain, in a manner that is dependent upon the Cys186
residue of c-H-ras exon (E) 4A (Barbacid, 1987; Lowy
and Willumsen, 1993). As a result of the importance
of the E4A exon in the activity of p21, any
modification of the Cys186 residue will result in marked
reduction in p21 activity (Barbacid, 1987; Lowy and
Willumsen, 1993).
The regulatory pathway of the c-H-ras gene by
alternative splicing was first described in 1989 (Cohen
et al., 1989). The D intron of the c-H-ras gene contains
an additional exon between (ras)E3 and (ras)E4A (see
Figure 1), named IDX. Thanks to this exon, the pre-
mRNA may be processed in at least two ways by an
alternative splicing reaction that may yield two mature
mRNAs: ras E0-E1-E2-E3-E4-E4B and ras E0-E1-E2-
E3-IDX-E4A-E4B. The (ras)IDX (intron D exon,
between exons E3 and E4A of the c-H-ras gene)
includes a premature stop-codon that may yield a
smaller truncated putative protein, p19, (see Figure 1).
The presence of the (ras)IDX exon in mature RNA
would result in the introduction of a termination codon
upstream of two subsequent exons. Therefore p19
mRNA may be subjected to nonsense-mediated decay
with consequent decreased baseline levels, yielding low
levels of p19 protein (Cohen et al., 1989). Although the
p19 protein has not yet been characterized, p19 cDNA
has been detected in a retinoblastoma library, in
human placenta and in rat brain, which confirms that
p19 mRNA is present (Cohen et al., 1989). The results
of in vivo transfection experiments suggest – as might
be expected – that activated p19 does not exhibit
transforming activity (Cohen et al., 1993), presumably
because the protein does not contain (ras)E4A and is
thus unable to anchor correctly to the inner membrane.
Since the presence of the (ras)IDX inside the D intron
of the c-H-ras gene is conserved in dierent species
(human, rat, mouse and hamster), and two alternative
mRNAs have been detected, it is possible that
Oncogene (2001) 20, 3683 – 3694
ª 2001 Nature Publishing Group All rights reserved 0950 – 9232/01 $15.00
www.nature.com/onc
*Correspondence: M Bach-Elias, IIBB-CSIC, c/Jorge Girona
Salgado 18-26, 08034 Barcelona, Spain
Received 4 January 2001; revised 27 February 2001; accepted 15
March 2001
(ras)IDX participates in the fine tuning of the
regulation of this gene (Cohen et al., 1989).
In a recent report it was demonstrated – by stable
and transient transfection with expression vectors
containing external cDNA (without introns) – that
the p19 protein is expressed in human 293 cells (Huang
and Cohen, 1997). These results suggest that the p19
protein may be a negative regulator of p21.
It has been shown that a newly developed, natural
splicing reaction (that is thought to involve unconven-
tional splicing) might play a role in the expression of
some mammalian genes, when performed in combina-
tion with the cis-splicing process (Akopian et al., 1999;
Breen and Ashcroft, 1997; Caudevilla et al., 1998;
Kawasaki et al., 1999; Li et al., 1999; Shimizu and
Honjo, 1993; Sullivan et al., 1991; Vellard et al., 1992;
Zaphiropoulos, 1999; Frantz et al., 1999). One example
is rat carnitine octanoyltransferase (COT) pre-mRNA,
which undergoes a natural trans-splicing (Caudevilla et
al., 1998) process that yields three COT mRNAs: one
with a duplication of the COT E2 exon (....E2-E2...); a
second with a duplication of the COT E2-E3 exons
(...E2-E3-E2-E3...) and a third with no exon duplica-
tion. In mammals, trans-splicing can be used to
reprogram or interfere with specific pre-mRNAs, thus
modifying or completely changing the gene expressed
(Puttaraju et al., 1999; Mansfield et al., 2000). In the
reprogramming of the target pre-mRNA, it is first
necessary to establish which exons of the target pre-
mRNA are susceptible to involvement in a trans-
splicing reaction. Many external trans-RNAs (i.e. a
trans-donor or a trans-acceptor that will participate in
a trans-splicing reaction) can be synthesized to interfere
with other pre-mRNAs (Bruzik and Maniatis, 1995;
Chiara and Reed, 1995; Eul et al., 1995). In the work
described here, however, we have chosen a recently
discovered natural COT trans-donor and trans-accep-
tor to study the eects of interference with the D
intron of the H-ras gene. The COT trans-donors/
acceptors were chosen because when tested against
other trans-RNAs, they proved to be strong donors
and acceptors (this paper and Codony et al., 2001,
unpublished data). Thus, by using either (COT)E2 or
(COT)E3 as a donor, and (COT)E2 as an acceptor (in
a heterologous trans splicing-reaction), we were able to
establish which segment of the H-ras terminal region
can be invaded by trans-splicing. In these trans-splicing
assays, we have used the E3-D1 intron-IDX-D2 intron-
E4A sequence from the H-ras gene, since interruption
of the D2 intron may yield a protein without (ras)E4A,
and thus reduce the levels of transforming p21 protein.
Thus, the invasion of pre-mRNAs by reprogrammed
trans-RNAs (donors or acceptors) might allow the
modulation of a harmful message. The primary aim of
this study was to investigate whether natural or
reprogrammed trans-exons can invade harmful mRNA
specifically to modulate its abundance. The pre-
mRNAs we chose to be deactivated were the terminal
sequence of the human H-ras oncogene, D intron, and
flanking sequences (see Figure 1). If more p19 mRNA
is obtained (with the IDX therefore being included in
the mature message by splicing of the D1 intron),
activated mRNAs have less tumorigenic activity
(Cohen et al., 1993). Therefore, if the degree of D
splicing is reduced, the pathway to p19 mRNA
activation should be favoured. The first step of this
work was to establish whether some of the terminal
exons of H-ras could participate in a heterologous
trans-splicing reaction.
Results
An in vitro cis-splicing assay of the D intron of H-ras
In order to test how trans-RNAs (donors or acceptors,
shown in Figure 2) invade the cis-splicing machinery,
we first developed an in vitro cis-splicing assay with a
mini-gene containing the E3-D intron-E4A sequence of
the H-ras gene. Figure 3 shows, for the first time, in
vitro cis-splicing of the D intron of the H-ras gene in
HeLa nuclear extracts with the K pre-mRNA. We
detected a greater abundance of the (ras)E3-(ras)E4A
cis-product than of the (ras)E3-(ras)IDX-(ras)E4A cis-
product (Figure 3, lane 2). This suggests that in these in
vitro conditions in HeLa cell nuclear extracts, the
excision of the D intron is more ecient than the
excision of the D1+D2 introns (see Figure 1 and
Cohen et al., 1993). All of the intermediate and
product bands obtained from the first and second
steps of the cis-splicing reaction (Figure 3, lane 2),
including lariats, were mapped by RT –PCR and DNA
sequencing.
The (ras) E4A acceptor trans-splices, performed in vitro
with a heterologous trans-donor
Our first approach was to see whether the D intron
(D1+D2) or the D2 intron of H-ras is invaded by
trans-splicing with the natural (COT)E2 trans-donor,
as determined by an in vitro trans-splicing assay. In the
in vitro trans-splicing reactions shown in Figure 4a, the
K and L pre-mRNAs were used as acceptors, and the
Figure 1 Alternative splicing of the D intron in c-H-ras pre-
mRNA
Modulation of H-ras oncogene
C Codony et al
3684
Oncogene
A pre-mRNA was the donor. In this experiment we
also assayed the (N4=G) mutant that is described
elsewhere (Cohen et al., 1989). The (N4=G) mutant
was isolated from a tumour expressing activated H-ras,
and contains a mutation on the fourth base (N4=G)
of the (ras)IDX 5’splice site (5’SS), where an adenosine
residue was changed to guanosine. Activated (N4=G)
mutant pre-mRNA was described as having a higher
transformation capacity than the activated wild-type
(wt) gene (N4=A). It has been suggested that the
(N4=G) mutation aects p21 expression, by lowering
D2 intron splicing (Cohen et al., 1989). We therefore
wanted to study how this mutation aects the trans-
splicing reaction. The mutation was present in both the
K and L constructions. Thus we performed a trans-
splicing attack of the natural donor (COT)E2 (A pre-
mRNA) to the pre-mRNAs containing intron D (K
pre-mRNAs) or to the pre-mRNAs containing intron
D2 (L pre-mRNAs), which contained both the wt
(N4=A) and (N4=G) mutant sequences. The A donor
trans-spliced well with acceptor (ras)E4A (see Figure 4,
lanes 3 – 17). This trans-splicing reaction had a higher
eciency with the L construction than with K pre-
mRNA, probably because the 5’SS sequence of the
(ras)IDX is weaker tha that of the (ras)E3 exon when
it has to splice up the (ras)E4A exon [see also Figure 3,
which shows that (ras)E3-(ras)IDX-(ras)E4A is less
abundant than (ras)E3-(ras)E4A]. Therefore, the A
donor competed better with D2 intron splicing than
with D intron splicing. The product (COT)E2-(ras)IDX
was not detected with any of the pre-mRNAs used,
which suggested initially that the (ras)IDX acceptor did
not splice well with this donor (this observation was
studied further in the experiments described below). No
significant dierences were seen between the wt
(N4=A) and mutant (N4=G) pre-mRNAs (Figure
4a: compare lanes 3 – 5 with lanes 6 – 9, and lanes 10 –
13 with lanes 14 – 17).
The (ras)E4A could be both an acceptor and a donor and
is able to attack itself in successive rounds of in vitro
trans-splicing
A second band was detected above the (COT)E2-
(ras)E4A product band in this trans-splicing assay
(Figure 4a, lanes 12, 13, 16 and 17). Sequencing of the
upper band revealed that it corresponds to a second
round of trans-splicing reaction in which the (COT)E2-
(ras)E4A product re-attacked the L pre-mRNA,
duplicating (ras)E4A and yielding the product
(COT)E2-(ras)E4A-(ras)E4A (Figure 4a, lanes 12, 13,
16 and 17). This reaction is made possible by the fact
that the L pre-mRNA contains a 5’SS sequence
hanging from the (ras)E4A exon that is also present
in (COT)E2-(ras)E4A. This band is hard to see in
Figure 2 Pre-mRNAs tested in this work. K and L pre-mRNAs
contained identical 5’ splice sites (5’SS). The (ras)E4a exon has
been abbreviated in all the figures, to rasE4. Constructs K and L
are basically equivalent in sequence, except for the addition of
(ras)E3 and complete D1 intron in K
Figure 3 In vitro cis-splicing assay of the D intron of H-ras.
Lane 1, control without ATP; lane 2, with ATP [K pre-mRNA,
wt (5 fmol)]. The two bands of 285 and 390 nucleotides (nt)
correspond to the (ras)E3-(ras)E4A and (ras)E3-(ras)IDX-
(ras)E4A products, respectively. The lariat product was mapped
by reverse transcriptase-polymerase chain reaction (RT–PCR),
and it can be observed on the upper part of the gel. The
molecular weight markers are shown to the left of the figure. All
bands were excised from the gel, eluted and then mapped by
RT–PCR (with 4+6 or 5+6 primers) and DNA sequencing.
Intron D products, either branched or debranched, were
sequenced with intron D specific primers (our unpublished
results). A 5% acrylamide gel was used here
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Figure 4 (a) The (COT)E2 donor trans-splices in vitro with the H-ras D intron. Radio-labelled A (11.5 fmol) donor was incubated
with increasing amount of the wt (N4=A) or mutant (N4=G) forms of the cis-splicing K and L pre-mRNAs. The mutant (N4=G)
form has an adenosine-to-guanosine mutation in position 4 of the 5’SS sequence of the D2 intron. Lane 1 is the negative control
(without ATP). Lane 2 is a non-related RNA (J in Figure 2, but containing an additional stretch of the polylinker region of
Bluescript SK7) that was used as a length marker of 352 nt. Lanes 3 – 5 are increasing amounts of K (wt, N4=A) pre-mRNA
(0.16, 0.31 and 0.62 pmol, respectively); lanes 6 – 9 are increasing amounts of K mutant (N4=G) pre-mRNA (0.08, 0.16, 0.31 and
0.62 pmol, respectively); lanes 10 – 13 are increasing amounts of L (wt, N4=A), and lanes 14 – 17 are increasing amounts of L
mutant (N4=G) pre-mRNAS (0.1, 0.2, 0.4 and 0.8 pmol, respectively). The figure shows the bands corresponding to the (COT)E2-
(ras)E4A and (COT)E2-(ras)E4A-(ras)E4A products. Products were mapped by RT–PCR (with 1+6 primers) and DNA
sequencing. An 8% acrylamide gel was used here. (b) Second trans-splicing round of the (ras)E4A exon. The radio-labelled bands
corresponding to the products, and (ras)E3-(ras)E4A, E pre-mRNA, (COT)E2-(ras)E4A and G pre-mRNA (from Figures 3 and 4a,
respectively) were cut from the gels, eluted and purified. The purified bands were incubated with non-radio-labelled wt (N4=A) L
pre-mRNA or mutant (N4=G) L pre-mRNA. Lanes 1 – 4 correspond to (COT)E2-(ras)E4A donor, and lanes 5 – 8 to (ras)E3-
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trans-splicing with K pre-mRNA, probably because
this construct results in the production of a smaller
amount of trans-splicing product (compare lanes 3 – 9
with lanes 10 – 17), and also because cis-splicing of the
D intron, in vitro, is far more ecient than of the D2
intron (see Figure 3 above and Guil et al., 2001,
unpublished results).
RT –PCR amplification of the RNA products
obtained from in vitro cis-splicing reactions of L pre-
mRNA (without adding the trans-donor A) yielded the
(ras)IDX-(ras)E4 cis-product. However, little (ras)E4A-
(ras)E4A trans-product was detected (data not shown).
This indicates that the homologous (ras)E4Ax(ras)E4A
trans-splicing of L pre-mRNA is very inecient under
these conditions. Therefore, duplication of the (ras)E4A
exon is not favoured during the cis-splicing reaction, but
the amount of duplicated (ras)E4A exon may be
increased when a heterologous trans-donor starts a
trans-splicing reaction with the (ras)E4A acceptor. This
suggests that once an exon has started a trans-splicing
event, the product of this reaction may undergo
successive trans-splicing rounds if it still has a 5’SS
sequence. In accordance with this hypothesis, we found
a third band above the (COT)E2-(ras)E4A-(ras)E4A
product (Figure 4a, arrowhead in lanes 16 and 17)
which has a length that is compatible with a trans-
spliced (COT)E2-(ras)E4A-(ras)E4A-(ras)E4A product,
containing three (ras)E4A exons.
In order to better demonstrate that the trans-splicing
(COT)E2-(ras)E4A product – which contains a 5’SS
sequence hanging from the (ras)E4A exon (Figure
4a) – can be a donor in a second trans-splicing event,
this band was cut from the gel and re-assayed as a
trans-splicing donor. In addition, the (ras)E3-(ras)E4A
cis-product (see Figure 3), which also contained a 5’SS
sequence hanging from the (ras)E4A exon, was assayed
in parallel as a trans-exon donor and compared with
the (COT)E2-(ras)E4A trans-product (the product of
the first trans-splicing round described in Figure 4a). In
both cases the L pre-mRNA was used as the acceptor
(see drawing in Figure 4b). Both donors performed a
second trans-splicing round with the (ras)E4A 3’SS
sequence of the L pre-mRNA acceptor (Figure 4b,
lanes 3, 4, 7 and 8), yielding (COT)E2-(ras)E4A-
(ras)E4A and (ras)E3-(ras)E4A-(ras)E4A. The trans-
splicing products (COT)E2-(ras)E4A-(ras)E4A and
(ras)E3-(ras)E4A-(ras)E4A yielded a double band
which, after RT –PCR sequencing, proved to be the
same product; the high mobility bands were the result
of some nucleotide degradation at the 3’ end. Again,
some minor bands were observed above the trans-
splicing products (Figure 4b, arrowheads in lanes 3, 4,
7 and 8) with molecular weights that were compatible
with a third round of trans-splicing that may include a
third (ras)E4A. No remarkable dierences were
observed between wt (N4=A) and mutant (N4=G);
therefore, no more experiments were performed with
the (N4=G) mutant.
To determine whether the capability of the (ras)E4A
and its 5’SS sequence to be a trans-donor is due to its
own sequences or to enhancer sequences present in
(COT)E2 (in G pre-mRNA) or in (ras)E3 (in E pre-
mRNA), both located upstream of (ras)E4A,
trans-splicing reactions were performed with (ras)E4A
alone. The F pre-mRNA, which contained neither the
(COT)E2 nor (ras)E3 sequences, was reacted with the
L pre-mRNA (see drawing in Figure 4c ) and the
results were compared with those shown in Figure 4b.
The (ras)E4A donor trans-spliced with the (ras)E4A
acceptor of the L pre-mRNA (see lanes 3 – 6 in Figure
4c); thus the (ras)E4A and flanking regions are a trans-
RNA that has the capacity to be either the donor or
the acceptor in a heterologous trans-splicing reaction
that may yield mRNAs with duplicated (ras)E4A.
Again a minor band with a molecular weight that was
compatible with a second trans-splicing round was
observed above the first trans-splicing product.
We tested whether the (ras)E4A exon was duplicated
in vivo in human mRNA. We performed PCR
amplifications with cDNAs obtained from the HeLa
S3 cell line ATCC CCL2 (Clontech). In all of the
assays performed we found the p21 mRNA, but we
detected no duplication of the (ras)E4A exon in the
expressed cDNAs of this cell line (not shown). We also
did not detect (ras)E4A duplications in genomic human
DNA.
The (ras)IDX acceptor does not trans-splice with other
heterologous donors
The observation that the (ras)IDX acceptor does not
splice with the (COT)E2 donor was studied further in
the following experiments. When we analysed the
sequences of the (ras)IDX and the flanking regions,
we observed that the (ras)IDX is 82 nucleotides (nt)
long (Cohen et al., 1989). Work performed by Chiara
and Reed (1995) with an adenovirus mini-gene has
shown that an in vitro trans-splicing reaction may
(ras)E4A donor. Lanes 1 and 5 are negative controls without ATP. Lanes 2 and 6 are negative controls without acceptor. Lanes 3
and 7 were incubated with wt (N4=A) L pre-mRNA (1.4 pmol), and lanes 4 and 8 with mutant (N4=G) L pre-mRNA (1.4 pmol).
The figure shows trans-splicing products with both donors (E and G pre-mRNAS and acceptors – wt (N4=A) and mutant
(N4=G). All bands were excised from the gel, eluted and then mapped using RT–PCR (with the same primers as described in the
legends of Figures 3 and 4a) and DNA sequencing. Doublet bands, as shown elsewhere (Caudevilla et al., 1998), were mapped by
RT–PCR and contained the same sequence, with the exception of some nucleotide degradation at the 3’ end. An 8% acrylamide gel
was used here. (c) The (ras)E4A donor trans-splices in vitro with the (ras)E4A acceptor. Radio-labelled F donor (11.5 fmol) was
incubated with increasing amounts of the wt L pre-mRNA, lanes 3 – 6 (0.18, 0.36, 0.73 and 1.46 pmol, respectively). Lane 1 is the
negative control without ATP, and lane 2 is the negative control without acceptor. All bands were excised from the gel, eluted and
then mapped by RT–PCR (with 7+6 primers) and DNA sequencing. A 6% acrylamide gel was used here
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Figure 5 (a) An enhancer sequence element (ESE) – but not a 5’SS enhancer – activated the (ras)IDX and flanking sequences to
participate as an acceptor in a trans-splicing reaction. Increasing amounts of radio-labelled N (205 nt) and O (210 nt) acceptors
were tested against non-radio-labelled C donor. Lane 1 was the negative control without ATP, with 440 fmol of the N acceptor.
Lanes 2 – 5 were increasing amounts of radio-labelled N acceptor (55, 110, 220 and 440 fmol, respectively) with C donor
(1.75 pmol). The trans-splicing product had 261 nt, as confirmed by RT–PCR (with 3+8 primers) and DNA sequencing. Lanes 6 –
9 were a similar experiment with radio-labelled O trans-acceptor (the expected product of the C6O reaction should have 237 nt).
An 8% acrylamide gel was used here. (b) The (ras)IDX modified with an ESE sequence is a poor acceptor compared with the
natural (COT)E2 acceptor. Radio-labelled A donor (14.4 fmol) was incubated with increasing amounts of non-radio-labelled N
acceptor (75, 150, 300 and 600 fmol in lanes 2 – 5, respectively) or J acceptor (75, 150, 300 and 600 fmol in lanes 6 – 9, respectively).
Lane 1 is the control (without ATP) of the A6N reaction (600 fmol of N). The products were confirmed by RT–PCR (with 1+8
primers in the A6N reaction, and with 1+2 in the A6J reaction) and DNA sequencing. The double bands are due to some
nucleotide degradation at the product 3’ end (Caudevilla et al., 1998). An 8% acrylamide gel was used here. (c) Competition of the
(ras)IDX-ESE and (COT)E2 acceptors with the (ras)E3 donor. (ras)E3 trans-spliced better with the (COT)E2 acceptor than with the
(ras)IDX-ESE acceptor. Radio-labelled D donor (10.1 fmol in all lanes) was incubated with increasing amounts of non-radio-
labelled N or J acceptors. Lane 1 was the negative control without ATP. Lanes 2 – 6 were increasing amounts of the N acceptor
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occur in human extracts, with an acceptor containing a
3’SS sequence and a 5’SS sequence separated by 50 nt.
Although the distance between the 3’SS and 5’SS
sequences in the (ras)IDX is greater than 50 nt, we first
studied whether the (ras)IDX and flanking sequences
could act as a 3’SS acceptor for several 5’SS donors.
For this study, four trans-donors were chosen as
partners of the (ras)IDX acceptor in trans-splicing
reactions, for the following reasons: (1) previous
studies have shown that (adenovirus) C pre-mRNA is
an in vitro trans-donor (Chiara and Reed, 1995), (2)
(COT)A and (COT)B pre-mRNAs are in vivo natural
trans-donors that trans-splice in vitro (Caudevilla et al.,
1998), and (3) (ras)E3 is the natural 5’SS partner of the
(ras)IDX in a cis-splicing reaction.
The trans-splicing reactions between pre-mRNAs C
and M, D and M, A and M, and B and M yielded no
trans-splicing products (our unpublished results). This
assay was also performed at several dierent donor
concentrations, with the same result (data not shown).
Thus, the (ras)IDX acceptor is a weak 3’SS partner for
the four donors tested in an in vitro trans-splicing assay.
In order to determine whether the separation of
82 nt between the 3’SS and the 5’SS sequences in the
(ras)IDX was the cause of its failure as a trans-
acceptor, we created the (O) pre-mRNA, which
contained a 5’SS that was 50 nt away from the 3’SS
of the (ras)IDX. Figure 5a shows that radio-labelled O
pre-mRNA did not function as a trans-acceptor of the
adenovirus C pre-mRNA donor (see lanes 6 – 9). The
expected product of a C6O trans-splicing would have
been a 237-nt molecule, which was not detected in the
present study. The C6O trans-splicing experiment was
performed with other donors and under other condi-
tions, but still no products were obtained (data not
shown). These results indicate that the presence of a
5’SS near a 3’SS does not necessarily activate the in
vitro trans-splicing of the (ras)IDX.
A (ras)IDX acceptor, modified with an enhancer
sequence element, trans-splices in vitro
A second feature that is thought to be important for an
in vitro trans-splicing reaction in mammalian cells with
conventional pre-mRNAs is the presence of an
enhancer sequence element (ESE), such as (GAR)n,
near the 3’SS of the trans-acceptor (Bruzik and
Maniatis, 1995; Chiara and Reed, 1995). The (ras)IDX
contains no (GAR)n repeats in its sequence. Therefore,
the ESE sequence of the ASLV (Tanaka et al., 1994)
was added to the (ras)IDX, 50 nt away from its 3’SS,
in order to determine whether this sequence could
activate trans-splicing of the (ras)IDX. This molecule
was named N pre-mRNA. It has been reported that
the ESE sequence of ASLV is a trans-splicing activator
(Bruzik and Maniatis, 1995; Chiara and Reed, 1995).
The trans-splicing reaction of C6N pre-mRNAs (N
pre-mRNA being radio-labelled) resulted in a radio-
labelled band with a length of around 261 nt (Figure
5a, lanes 2 – 4), which corresponded to the (adenovir-
us)5’Ad-(ras)IDX-ESE trans-spliced product. This in-
dicated that (ras)IDX 3’SS could be activated by
proteins that bind to ESE boxes located in the
modified (ras)IDX, which then becomes a trans-
acceptor in an in vitro trans-splicing reaction.
Two natural trans-donors (i.e. donors that perform
natural trans-splicing in vivo) were also assayed with
the N pre-mRNA containing the modified (ras)IDX-
ESE acceptor: the SL RNA from Ascaris lumbricoides
and COT donor A. A minor trans-splicing product was
obtained when the SL RNA6N reaction was assayed
(results not shown), but only a very small amount of
trans-splicing product was detected in the trans-splicing
of A6N (see Figure 5b, lanes 2 – 5, product indicated
with an arrowhead on the right)) as compared with the
natural trans-splicing reaction (COT)E26(COT)E2, –
the reaction of A6J pre-mRNAs, described in
(Caudevilla et al., 1998) – which was also included
as a control trans-splicing reaction in lanes 6 – 9 of
Figure 5b. Again, double bands were attributable to
nucleotide degradation at the product 3’ end, as stated
elsewhere (Caudevilla et al., 1998). These results
indicate that, firstly, a 5’SS 50 nt away from the 3’SS
(ras)IDX is not sucient to activate it as an acceptor
in a trans-splicing reaction. The activity of the 5’SS as
an enhancer sequence in trans-splicing reactions is
therefore dependent upon the acceptor sequences and
the donor partner. Second, some combinations of
partners are more ecient in yielding mammalian
trans-splicing products (see Figure 5b, compare lanes
2 – 5 with lanes 6 – 9). Third, with some donors, the
addition of an ESE enhancer box induces the (ras)IDX
to become an acceptor in an in vitro trans-splicing
reaction. From these results we concluded that with the
donors tested, the (ras)IDX and its flanking sequences
are not a good trans-splicing acceptor (at least in vitro),
and that this exon is not the best choice for an external
trans-RNA attack.
(ras)E3 acts as a trans-splicing donor in an in vitro
trans-splicing reaction
The ability of (ras)E3 and its flanking 5’SS sequences
to behave as a trans-donor in an in vitro trans-splicing
reaction was also studied. As mentioned above, the wt
(ras)IDX acceptor did not trans-splice with its natural
cis-splicing 5’ exon partner, (ras)E3 (unpublished
results). Nevertheless, the artificial and modified
(0.75, 1.5, 3, 6 and 12 pmol, respectively). Lanes 7 – 11 were increasing amounts of the J acceptor (0.5, 1.1, 2.2, 4.4 and 8.9 pmol,
respectively). Lanes 12 – 16 were increasing, but always equimolar amounts of both N and J acceptors (each 0.5, 1.1, 2.2, 4.4 and
8.9 pmol, respectively). The bands were confirmed by RT–PCR (with 5+8 primers in the D6N reaction, and with 5+2 primers in
the D6J reaction) and DNA sequencing. The double bands are due to some nucleotide degradation at the product 3’ end
(Caudevilla et al., 1998). An 8% acrylamide gel was used here
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(ras)IDX-ESE (N pre-mRNA) was a trans-acceptor for
the (ras)E3 donor (D pre-mRNA). The D6N trans-
reaction yielded the expected product (see Figure 5c,
lanes 2 – 6), and the in vivo natural (COT)E2 also
proved to be a trans-acceptor for the (ras)E3 donor
(i.e. D6J trans-reaction, lanes 7 – 11). However, when
both acceptors were used in competition in front of the
(ras)E3 donor (by using increasing and equimolar
amounts of N and J acceptors and 10.1 fmol of D
donor; i.e. D6J6N), the D6N product remained
almost undetected (Figure 5c, lanes 12 – 16), and the
abundance of the D6J product was much greater
(Figure 5c: compare lanes 1 – 11 with lanes 12 – 16).
The inhibition eect seen by increasing the amounts of
J acceptor (in lanes 9 – 11 and lanes 15 and 16) is a
general behaviour of all of the dierent trans-splicing
donor and acceptor pairs that we have tested so far. N
acceptors also inhibit trans-splicing at higher concen-
trations than those shown in lanes 2 – 6 (our unpub-
lished results), and this inhibition eect is dependent
upon the sequence of each donor/acceptor pair. The
dierences in the abundance of product obtained
indicate that J pre-mRNA is a stronger acceptor of
the (ras)E3 donor (D pre-mRNA) than is N pre-
mRNA. In an in vitro trans-splicing reaction, the
(ras)E3 donor (D pre-mRNA) prefers to pair with the
in vivo natural trans-acceptor (COT)E2 (i.e. with a
heterologous exon) than with its proper 3’SS cis-exon
(ras)IDX [in this case, the mutated (ras)IDX-ESE].
This result is in accordance with the results obtained
with the (ras)IDX and flanking sequences, which
proved to be weak, and remains quite weak even after
the introduction of the enhancer sequences.
A reprogrammed (COT)E2 donor modulates the
cis-splicing reaction of the H-ras D intron
As has been reported recently, trans-splicing may be a
useful tool for gene reprogramming since it can
modulate ‘sick’ pre-mRNAs via externally manipulated
trans-RNAs (Puttaraju et al., 1999). Since the activated
H-ras is a ‘sick’ message, we also investigated whether
a trans-splicing reaction could modulate pre-mRNA
cis-splicing of the H-ras D intron. To do this, the main
point to establish is whether a targeted trans-donor can
trans-splice to a H-ras D intron and, at the same time,
decrease the abundance of (ras)E3-(ras)E4 product.
With this aim, we reprogrammed the (COT)E2 so that
it specifically targeted the H-ras D intron. This
reprogrammed trans-RNA contained the natural
(COT)E2 donor coupled to an additional sequence
that recognized the (ras)D intron. This sequence was
added to the 3’ end of the A pre-mRNA, allowing a
70-nt base pairing with an internal region of the D
intron (H pre-mRNA, see drawing in Figure 6). As a
trans-donor control, a similar chimeric trans-donor was
constructed, but with an inverted base-pairing region
added, so that the trans-donor could perform trans-
splicing but with no specificity for the D intron
sequence. This latter construct did not contain the
sequence that allowed 70-nt base pairing (I pre-mRNA;
represented in Figure 6 by an inverted arrow). Both
trans-exons were tested with the wt (N4=A) acceptor
K pre-mRNA, which performed cis-splicing at the
same time as the trans-splicing reaction (as indicated in
Figure 3). Therefore, the trans-splicing reaction would
compete with the cis-machinery. As shown in Figure 6,
the (COT)E2 donor that allows base pairing with 70 nt
of the D intron can compete with the cis-splicing
reaction (ras)E3-(ras)E4A (compare lanes 2 and 4 in
Figure 6), with a reduction in the abundance of the cis-
product of around 50% (as quantified by densitome-
try). In three independent experiments, the (E2) donor
that does not allow base pairing caused a reduction in
the cis-splicing product of around 25%. This indicates
Figure 6 A reprogrammed (COT)E2 donor inhibits the D intron
cis-splicing of H-ras. The radio-labelled K pre-mRNA (wt,
2.12 fmol) was incubated with 0.55 pmol of non-radio-labelled I
and H donors (lanes 1 and 2, respectively). Lane 4 was the
positive control with no added trans-donor. The Figure shows the
(ras)E3-(ras)E4A cis-splicing product in lanes 1, 3 and 4, (ras)E3-
(ras)IDX-(ras)E4A product in lane 4, and the (COT)E2-(ras)E4A
trans-splicing product in lane 2. Lane 3 was the negative control
without ATP and added donors. The bands were cut from the gel
and mapped by RT–PCR, with 5+6 primers for the (ras)E3-
(ras)IDX-(ras)E4A cis-splicing products and with 1+6 primers
for the (COT)E2-(ras)E4A trans-spliced product, and DNA
sequencing. A 5% acrylamide gel was used here. The autoradio-
graphy was scanned with a Molecular Dynamics laser densit-
ometer using the integration function in the ImageQuant
programme to determine peak areas. The integrated areas of the
bands corresponding to the products were used to calculate the
percentage of inhibition (described in Results) compared to the
product obtained in lane 4. Since the amount of the pre-mRNA
input may fluctuate, the amount of pre-mRNA K added was
taken into account when the percentage inhibition was calculated
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that the (COT)E2 exon can exert some level of
inhibition on cis-splicing, possibly by recruiting splicing
factors from the available pool. This trans-donor also
yielded the trans-splicing product (COT)E2-(ras)E4A
(see lane 2 in Figure 6), while the trans-donor without
the target sequence did not (compare lane 1 with lane 2
in Figure 6). The amount of radioactivity correspond-
ing to the (COT)E2-(ras)E4A trans-product (Figure 6,
lane 2) is not directly comparable with that of the
(ras)E3-(ras)E4A cis-product (Figure 6, lane 2). The
cis-product contains radio-labelled (ras)E3 and (ra-
s)E4A exons, whereas the trans-product contains a
non-radio-labelled (COT)E2 exon, which makes 50%
of the non-radio-labelled trans-product. This result
indicates that the base-pairing sequence chosen to
target the D intron allows trans-splicing, and that the
trans-exon down-modulates the cis-(ras)E3-(ras)E4A
product. At the same time, as expected, the base-
pairing target sequence increases the possibility that the
trans-donor performs trans-splicing to (ras)E4A.
Discussion
The H-ras oncogene contains exons that could,
potentially, be trans-spliced
The recent discovery that mammalian cells can perform
trans-splicing naturally has incalculable consequences.
It implies that the cell may be creating many RNA
forms that have not yet been detected, and may be able
to modify, create or modulate the expression or
function of a protein. As described above, the H-ras
oncogene is quite an interesting gene with regard to
splicing. With the aim of invading the H-ras D intron,
(ras)E3, (ras)IDX and (ras)E4A and flanking sequences
were tested by in vitro trans-splicing with external trans-
exons. As a ‘fish-hook’, we used the natural (COT)E2
exon to determine whether the (ras)E3, (ras)IDX and
(ras)E4A exons and their flanking sequences could be
trans-spliced with an external trans-RNA. As discussed
above, the (ras)IDX and flanking sequences are not
good trans-acceptors for all of the tested trans-donors.
However, (ras)IDX is trans-spliced by adding an ESE
purine-rich ehancer to this exon. Similar results have
been obtained previously with other trans-RNAs
(Bruzik and Maniatis, 1995; Chiara and Reed, 1995),
which indicates that ESE purine-rich enhancers could
activate trans-splicing events. The (ras)E3 and (ras)E4A
exons and their flanking sequences proved to be good
donors and acceptor/donors, respectively, for the COT
trans-RNAs. The natural trans-spliced (COT)E2 con-
tains three ESE sequences that follow the (GAR)n rule
(Caudevilla et al., 1998), and more recent results
demonstrate that at least one of these boxes could be
essential for natural trans-splicing (Caudevilla et al.,
2001, unpublished results). The (ras)E4A exon also
contains purine-rich regions that might have a role as
enhancer elements in cis- and trans-splicing, although
this has not yet been studied. In conclusion, not all
exons can be invaded by external trans-RNAs and, so
far, the ESE boxes seem to play an important role in
the activation of natural and externally designed trans-
splicing events.
An interesting discovery was made with the trans-
splicing of the (ras)E4A acceptor. After a first round of
trans-splicing between the (COT)E2 donor and the
(ras)E4A acceptor, a second round of trans-splicing
was obtained between the product of the first trans-
splicing reaction and the 3’SS of the (ras)E4A exon, a
phenomenon we called successive trans-splicing rounds.
Curiously, we also observed that it is even possible to
obtain more trans-splicing rounds from the products of
the previous trans-splicing reactions. Similar results
have been found by one of us (A Graessmann) in vivo
with the natural adenovirus trans-splicing reactions
(data not shown), where successive trans-splicing
rounds were also detected. In addition, Chiara and
Reed (1995) also suggested that this phenomenon
occurs in conventional adenovirus mini-genes. In
explanation, since the nuclear machinery should splice
out the introns, the 5’SS that hangs from the (COT)E2-
(ras)E4A and (ras)E3-(ras)E4A products is committed
to being spliced out. Therefore, as the available 3’SS
exon may also contain a hanging 5’SS (in this work,
the K and L pre-mRNAs), the trans-splicing machinery
will perform successive trans-splicing rounds until the
pre-mRNA concentration becomes limiting. Thus, with
each successive round, the splicing machinery may
decrease the amount of free 5’SS.
This raises the question as to which circumstances
result in a 5’SS hanging from a pre-mRNA. This is not
the normal situation, but the existence of natural trans-
splicing implies that trans-donors and trans-acceptors
should be obtained as products from an initial trans-
splicing event between two cis pre-mRNAs. It should
then be possible to obtain a trans-donor (with a hanging
5’SS) that can contribute to successive trans-splicing
reactions. One event that may favour a trans-splicing
reaction is the nuclear definition of terminal exons. If
the first exon cannot be well defined, the second exon
may become a trans-acceptor with a hanging 3’SS. The
reverse may also occur; if the last exon is not well
defined, the penultimate exon may become a trans-
donor with a hanging 5’SS. A second event that may
also create hanging 5’SS or 3’SS sequences would be co-
transcriptional trans-splicing. In that case, two situa-
tions can be suggested: (a) a nearly nascent 5’SS may
trans-splice with external 3’SS sequences before the next
cis-3’ exon is synthesized by RNA polymerase II, and
(b), premature terminations of RNA polymerase II
inside intron DNA sequences may yield molecules with
a hanging 5’SS (Dye and Proudfoot, 1999).
Natural trans-exons may interfere with inconvenient
pre-mRNAs
As expected, our results show that trans-splicing
follows the cis-splicing rules; that is, some 5’ donor
and 3’ acceptor pairs are more easily spliced together
than others, and thus trans-splicing could join the most
convenient trans-exons, resulting in a modulation of
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the expression of a message. However, there is a critical
aspect that distinguishes trans- from cis-splicing
(leaving alternative splicing aside): during cis-splicing
it is clear that the 5’SS very often joins with the next
downstream 3’SS, probably via the presence of an
intron that links the 5’ exon with the 3’ exon. This
situation is quite dierent in trans-splicing, as there is
no intron that links the trans-donor with the trans-
acceptor. Trans-molecules should meet, and thus the
reaction is highly dependent upon the concentration of
trans-molecules. Furthermore, trans-donors/acceptors
should choose among several nearby sequences to
splice to the strongest pair for this specific trans-donor/
acceptor (see Figure 5c, lanes 12 – 16). This is
equivalent to a lock-and-key system. Therefore, if we
want to use a trans-RNA to interfere specifically with a
target pre-mRNA, it will be necessary to add sequences
that recognize specifically this pre-mRNA and allow
the trans-splicing with the target exons. This will
increase the concentration of trans-donors near the
target pre-mRNA and will promote the formation of
the selected donor/acceptor pair.
Reprogramming (COT)E2 at its 3’ end in such a way
that could allow base pairing with the (ras)D2 intron (H
pre-mRNA) has demonstrated its ability to compete with
the cis-splicing reaction to yield the (COT)E2-(ras)E4
trans-splicing product (Figure 6, lane 2). The (COT)E2
donor without the base-pairing stretch (I pre-mRNA),
however, did not show any appreciable amounts of the
(COT)E2-(ras)E4 trans-product (compare lane 1 with
lane 2 in Figure 6). In conclusion, the discovery that
(ras)E4A is capable of being a trans-donor and a trans-
acceptor in vitro may allow the modulation of H-ras pre-
mRNA cis-splicing by adding external trans-RNAs, such
as the reprogrammed (COT)E2 donor, which is
specifically designed to target the H-ras D intron. The
second product of the trans-splicing reaction that is
obtained in addition to (COT)E2-(ras)E4A is a pre-
mRNA that contains (ras)E3-(ras)D1-(ras)IDX-(ras)D2
(the D2 intron should contain a branched ‘Y’ lariat on it,
or it could be debranched). Although IDX behaves as a
weak exon, this later pre-mRNA could be further cis-
spliced to yield (ras)E3-(ras)IDX-(ras)D2 (with 736 nt;
only barely detected in this gel; our unpublished results).
These results indicate that it is possible (in vitro) to
attribute this alternative pathway partially to mRNA
that is similar to p19 mRNA (with a stop codon on
IDX), via external donor attacks. This trans-splicing
interference might yield the same consequences as the in
vivo alternative splicing of the D intron – i.e. the
activated H-ras gene will be less tumorigenic because
mRNA similar to p19 mRNA is being synthesized
(Cohen et al., 1989).
Materials and methods
Nuclear extracts and in vitro cis- and trans-splicing reactions
The active splicing extracts from HeLa cells were provided by
4C (Computer Cell Culture Center S.A., Mons, Belgium).
The cis- and trans-splicing reactions have been described in
detail elsewhere, (Caudevilla et al., 1998; Cicarelli et al.,
1998), respectively. All of the trans-splicing reactions
described here were carried out with one radio-labelled
partner and increasing amounts of the other non-radio-
labelled partner (in all Figures, an asterisk beside the pre-
mRNA indicates which RNA substrate is radio-labelled).
Pre-mRNAs
All H-ras gene sequences used in these experiments were
obtained from the human activated mutant 12 (Cohen et al.,
1989), which contains a mutation in codon 12 of (ras)E1.
This mutation does not aect the studies presented here, and
is thus not localized in the mini-gene constructions described
in Figure 2. All of the constructions used in this paper are
summarized in Figure 2 as trans-donors, trans-acceptors and
cis-splicing pre-RNAs. Since (ras)IDX is a real exon, the D
intron was divided into two introns, named D1 and D2
(Cohen et al., 1993).
In this work, a ‘donor’ is a trans-RNA that contains an
exon plus 5’SS sequences, and an ‘acceptor’ is an exon plus a
branch point, a polypyrimidine track and 3’SS sequences (see
Figure 2).
The constructs were prepared as follows: (A) was obtained
from the rat COT gene, as described elsewhere (Caudevilla et
al., 1998); (B) was obtained from the rat COT insert lgr5
(Caudevilla et al., 1998) using the Pfu polymerase and 11+12
primers (see below). A lgr5 fragment was obtained by
polymerase chain reaction (PCR), and subcloned in the
EcoRV restriction site of Bluescript SK(+) to obtain the pre-
B construct. In order to reduce the polylinker region, the pre-
B construct was first digested with SacI and EcoRI, and then
incubated with T4 DNA polymerase and religated with T4
DNA ligase. The latter plasmid was linearized with HindIII
and transcribed with T3 RNA polymerase. (C) was obtained
from the Ad1 plasmid, which was obtained from Adenovirus
(Konarska and Sharp, 1987); Ad1 was digested with HindIII,
and the fragment was subcloned in HindIII cut Bluescript
SK(7). This plasmid was linearized with KpnI and
transcribed with T3 RNA polymerase. For (D), the K
plasmid (described below) was linearized with NheI and
transcribed with T7 RNA polymerase. (E) was obtained as a
radio-labelled band (or splicing product) in a electrophoresis
gel that was run following an in vitro cis-splicing reaction of
pre-mRNA K in HeLa nuclear extract (see Figure 3). For
(F), the fragment obtained by PCR from L plasmid (see
below) with 7 (see below) and M13 (Stratagene) oligodeox-
yribonucleotides and Pfu polymerase, was cut with BamHI
and ligated to Bluescript (SK7), which had previously been
cut with Ec/136II and BamHI. The plasmid was linearized
with BamHI and transcribed with T3 RNA polymerase. (G)
was obtained as a radio-labelled band or product of a
electrophoresis gel that was run after an in vitro trans-splicing
reaction between A6L pre-mRNAs (see Figure 4a). For (H)
and (I), the L plasmid was first digested withPstI and BstEII
and then incubated with T4 DNA polymerase. The 70-base-
pair fragment was purified from the gel and ligated to the
plasmid A, which had previously been digested with EcoRI
and incubated with Klenow fragment. Both orientations of
the 70-bp insert were obtained: one was complementary to
the D2 intron (H pre-mRNA) and the other contained the
70-bp insert with the reverse sequence (I pre-mRNA). Both
plasmids were linearized with XmaI and transcribed with T3
RNA polymerase. (J) was obtained from the rat COT gene,
as described elsewhere (Caudevilla et al., 2001, unpublished
results). (K) was obtained from the human H-ras gene as
follows: 7ile12N and ile12N(G) are the pre-mRNAs wt
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N4=A and mutant N4=G, respectively, as described in
Results. The ile12N or ile12N(G) plasmids, which are
described elsewhere (Cohen et al., 1989), were first digested
with NcoI and NotI and then incubated with T4 DNA
polymerase. This fragment was ligated to Bluescript SK (7)
vector, which had previously been digested first with KpnI
and SmaI and then incubated with T4 DNA polymerase. The
plasmid was linearized with BamHI and transcribed with T7
RNA polymerase. For (l) plasmids ile12N or ile12N)G) were
digested first with NheI and NotI and second with T4 DNA
polymerase. The fragment was ligated to Bluescript SK (7)
vector, which had already been digested with Acc651 and
SmaI, and then with Klenow fragment. The plasmid was
linearized with BamHI and transcribed with T7 RNA
polymerase. For (M) plasmid L was linearized with PstI
and transcribed with T7 RNA polymerase. For (N) the avian
sarcoma-leukosis virus (ASLV) enhancer was obtained from
pSP72-ASLV (env 3’ exon) (Tanaka et al., 1994) that had
been cut with XbaI and HindIII, and the fragment was
subcloned in Bluescript SK (7) plasmid that had itself
previously been cut with XbaI and HindIII. This plasmid,
named pre-ASLV, was finally cut with XbaI. In order to
obtain the fragment containing the (ras)IDX, the K plasmid
was digested with NheI and XmaI, incubated with Klenow
fragment, and the (ras)IDX containing the fragment was
purified from a 1% agarose gel. This latter fragment was
subcloned in the pre-ASLV plasmid digested with XbaI. The
plasmid was cut with HindIII and transcribed with T3 RNA
polymerase. For (O) 2 oligodeoxyribonucleotide primers
(9+10, see below) corresponding to the mammalian 5’SS
consensus sequence were subcloned in the Bluescript SK (7)
plasmid that had been previously cut with NotI and BamHI.
This vector was cut with BamHI and then treated with
Klenow fragment to obtain pre-O. Plasmid ile12N was
digested with NheI and XmaI, and then treated with T4
DNA polymerase, and this fragment was subcloned in pre-O
plasmid. The plasmid O was linearized with NotI and
transcribed with T7 RNA polymerase.
Oligodeoxyribonucleotides used as primers for
reverse-transcriptase-PCR mapping of splicing bands
(described in the Figure legends) or plasmid constructions
(described above in Materials and methods)
(1) (COT)E2, sense, described elsewhere (Caudevilla et al.,
1998); (2) (COT)E2, antisense, described elsewhere (Caude-
villa et al., 1998); (3) (Adenovirus)Ad1, sense: TTGCATGC-
CTGCAGGTCGAG; (4) (ras)IDX, sense: GGCAGCCGCT-
CTGGCTCTAGCTCC; (5) (ras)E3, sense: ACGCACTGTG-
GAATCTCGGC; (6) (ras)E4, antisense: AGTCCCCCTCA-
CCTGCGTCA; (7) (ras)E4 sense: GGAGTGGAGGATGC-
CTTCT; (8) ASLV enhancer, antisense: CCTTCTTGCTTG-
TTGCTGGCG; (9) Consensus 5’ splice site (5’SS), sense:
GATCCGGGGTGAGTGGC; (10) Consensus 5’SS, anti-
sense: GGCCGCCACTCACCCCG; (11) (COT)E3, sense:
GGCGTACACATCGATTGAAGCCATTTGCAAATGAA-
GATTTT; (12) (COT)INTRON 3, antisense: AAGTATA-
CAAAATAAATACCCAG.
RNA gels and mapping of RNA bands
RNA denaturing gels were run in an electrophoresis system
as described elsewhere (Cicarelli et al., 1998). Gels of between
5 and 8% acrylamide were used – the specific percentages of
acrylamide used are indicated in each Figure legend. The
RNA bands from the radio-labelled products of the cis- and
trans-splicing reactions were characterized by reverse tran-
scriptase (RT) – PCR and DNA sequencing, as described
elsewhere (Caudevilla et al., 1998). The molecular weight
markers used were pBR322 digested with MspI.
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